Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers

OBJECTIVES: To compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor monoclonal antibody in development for SLE, in healthy volunteers. METHODS: In this Phase I randomised, placebo-controlled study, 30 adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tummala, Raj, Rouse, Tomas, Berglind, Anna, Santiago, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890854/
https://www.ncbi.nlm.nih.gov/pubmed/29644080
http://dx.doi.org/10.1136/lupus-2017-000252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890854/
https://www.ncbi.nlm.nih.gov/pubmed/29644080
http://dx.doi.org/10.1136/lupus-2017-000252

Ejemplares similares